Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer

Breast Cancer Research

Volumn 14, Issue 3, 2012, Pages

  Wu, Xiao ^a   Zhu, Zhengmao ^a   Li, Weidong ^c   Fu, Xiaoying ^b   Su, Dan ^a   Fu, Liya ^a   Zhang, Zhiqian ^a   Luo, Ang ^a   Sun, Xiaodong ^b   Fu, Li ^c   Dong, Jin Tang ^a,b  

^a NANKAI UNIVERSITY   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMODOMAIN HELICASE DNA BINDING PROTEIN 5; DNA BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENOMIC RNA; HELICASE; MESSENGER RNA; NERVE CELL ADHESION MOLECULE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VIMENTIN; CADHERIN; CHD5 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; NERVE PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; ZEB1 PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DISTANT METASTASIS; DNA METHYLATION; DOWN REGULATION; GENE DELETION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; SOMATIC MUTATION; BREAST TUMOR; CANCER INVASION; CELL TRANSFORMATION; CPG ISLAND; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; RNA INTERFERENCE; TUMOR CELL LINE;

BREAST NEOPLASMS; CADHERINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CPG ISLANDS; DNA COPY NUMBER VARIATIONS; DNA HELICASES; DNA METHYLATION; DNA-BINDING PROTEINS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; NEOPLASM INVASIVENESS; NERVE TISSUE PROTEINS; PROMOTER REGIONS, GENETIC; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; VIMENTIN;

EID: 84860611228     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3182     Document Type: Article

References (25)

1. Bagchi A, Mills AA. The quest for the 1p36 tumor suppressor. Cancer Res 2008, 68:2551-2556. 10.1158/0008-5472.CAN-07-2095, 2980353, 18413720.
2. Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D, Bredel M, Vogel H, Mills AA. CHD5 is a tumor suppressor at human 1p36. Cell 2007, 128:459-475. 10.1016/j.cell.2006.11.052, 17289567.
3. Marfella CG, Imbalzano AN. The Chd family of chromatin remodelers. Mutat Res 2007, 618:30-40. 10.1016/j.mrfmmm.2006.07.012, 1899158, 17350655.
4. Woodage T, Basrai MA, Baxevanis AD, Hieter P, Collins FS. Characterization of the CHD family of proteins. Proc Natl Acad Sci USA 1997, 94:11472-11477. 10.1073/pnas.94.21.11472, 23509, 9326634.
5. Denslow SA, Wade PA. The human Mi-2/NuRD complex and gene regulation. Oncogene 2007, 26:5433-5438. 10.1038/sj.onc.1210611, 17694084.
6. Thompson PM, Gotoh T, Kok M, White PS, Brodeur GM. CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene 2003, 22:1002-1011. 10.1038/sj.onc.1206211, 12592387.
7. Fujita T, Igarashi J, Okawa ER, Gotoh T, Manne J, Kolla V, Kim J, Zhao H, Pawel BR, London WB, Maris JM, White PS, Brodeur GM. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst 2008, 100:940-949. 10.1093/jnci/djn176, 2483574, 18577749.
8. Wang X, Lau KK, So LK, Lam YW. CHD5 is down-regulated through promoter hypermethylation in gastric cancer. J Biomed Sci 2009, 16:95. 10.1186/1423-0127-16-95, 2770510, 19840376.
9. Mulero-Navarro S, Esteller M. Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer. Epigenetics 2008, 3:210-215. 10.4161/epi.3.4.6610, 18698156.
10. Mokarram P, Kumar K, Brim H, Naghibalhossaini F, Saberi-firoozi M, Nouraie M, Green R, Lee E, Smoot DT, Ashktorab H. Distinct high-profile methylated genes in colorectal cancer. PLoS One 2009, 4:e7012. 10.1371/journal.pone.0007012, 2737306, 19750230.
11. Gorringe KL, Choong DY, Williams LH, Ramakrishna M, Sridhar A, Qiu W, Bearfoot JL, Campbell IG. Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. Neoplasia 2008, 10:1253-1258. 2570601, 18953434.
12. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274. 10.1126/science.1133427, 16959974.
13. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93:9821-9826. 10.1073/pnas.93.18.9821, 38513, 8790415.
14. Climent J, Perez-Losada J, Quigley DA, Kim IJ, Delrosario R, Jen KY, Bosch A, Lluch A, Mao JH, Balmain A. Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer. J Clin Oncol 2010, 28:3770-3778. 10.1200/JCO.2009.27.0215, 2917310, 20625127.
15. Chen C, Sun X, Ran Q, Wilkinson KD, Murphy TJ, Simons JW, Dong JT. Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells. Oncogene 2005, 24:3319-3327. 10.1038/sj.onc.1208497, 15735697.
16. Chen L, Zhu Z, Sun X, Dong XY, Wei J, Gu F, Sun YL, Zhou J, Dong JT, Fu L. Down-regulation of tumor suppressor gene FEZ1/LZTS1 in breast carcinoma involves promoter methylation and associates with metastasis. Breast Cancer Res Treat 2009, 116:471-478. 10.1007/s10549-008-0147-6, 2927198, 18686028.
17. Sun X, Frierson HF, Chen C, Li C, Ran Q, Otto KB, Cantarel BL, Vessella RL, Gao AC, Petros J, Miura Y, Simons JW, Dong JT. Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet 2005, 37:407-412. 10.1038/ng1528, 15750593.
18. Okawa ER, Gotoh T, Manne J, Igarashi J, Fujita T, Silverman KA, Xhao H, Mosse YP, White PS, Brodeur GM. Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. Oncogene 2008, 27:803-810. 10.1038/sj.onc.1210675, 17667943.
19. Bieche I, Khodja A, Lidereau R. Deletion mapping of chromosomal region 1p32-pter in primary breast cancer. Genes Chromosomes Cancer 1999, 24:255-263. 10.1002/(SICI)1098-2264(199903)24:3<255::AID-GCC11>3.0.CO;2-2, 10451706.
20. Forozan F, Mahlamaki EH, Monni O, Chen Y, Veldman R, Jiang Y, Gooden GC, Ethier SP, Kallioniemi A, Kallioniemi OP. Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. Cancer Res 2000, 60:4519-4525.
21. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 2003, 100:8621-8623. 10.1073/pnas.1633291100, 166359, 12861075.
22. Guo P, Dong XY, Zhang X, Zhao KW, Sun X, Li Q, Dong JT. Pro-proliferative factor KLF5 becomes anti-proliferative in epithelial homeostasis upon signaling-mediated modification. J Biol Chem 2009, 284:6071-6078. 2649083, 19056724.
23. Tsukamoto K, Ito N, Yoshimoto M, Kasumi F, Akiyama F, Sakamoto G, Nakamura Y, Emi M. Allelic loss on chromosome 1p is associated with progression and lymph node metastasis of primary breast carcinoma. Cancer 1998, 82:317-322.
24. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527. 10.1016/j.ccr.2006.10.008, 2730521, 17157791.
25. Koyama H, Zhuang T, Light JE, Kolla V, Higashi M, McGrady PW, London WB, Brodeur GM. Mechanisms of CHD5 Inactivation in Neuroblastomas. Clin Cancer Res 2012, 18:1588-1597. 10.1158/1078-0432.CCR-11-2644, 22294723.